Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

GNE-317

SKU: orb1300413

Description

GNE-317

Research Area

Signal Transduction

Images & Validation

Key Properties

CAS Number1394076-92-6
MW414.48
Purity99.42% (May vary between batches)
FormulaC19H22N6O3S
SMILESCOC1(COC1)c1sc2c(nc(nc2c1C)-c1cnc(N)nc1)N1CCOCC1
TargetPI3K|||mTOR
SolubilityDMSO:12.5 mg/mL (30.16 mM)

Bioactivity

In Vivo
Mice, which are i.c. inoculation with GL261-GFP-Luc cells Seven days later,are treated once daily with the maximum tolerated dose of GDC-0980 (7.5 mg/kg), GNE-317 (30 mg/kg), or vehicle. Tumor growth is tracked in GL261 through bioluminescence imaging on a weekly basis. There are no significant differences in GL261 tumor growth among the 3 groups treated by GDC-0980, GNE-317 or vehicle. The data show that the drugs have limited efficacy in inducing cell death in the GL261 cell line. Although GNE-317 has greater delivery and enhanced therapeutic targeting efficacy, it is not effective in the treatment of the GL261 tumor.
In Vitro
GNE-317, an oxetane derivative synthesized by GDC-0980, is aimed at reducing substrate affinity for efflux transporters. In vitro, GDC-0980 demonstrate similar profiles with GNE-317 in MTS cytotoxicity experiments using the GL261 cell line.
Cell Research
Cellular viability assays are set up in a 96-well format with 2000 GL261-GFP-Luc cells plated per well in the culture conditions. GL261, an aggressive C57BL/6J-derived glioma line, is transfected with both green fluorescent protein (GFP) and luciferase (Luc) from separate plasmids.GL261-GFP-Luc cells are cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS and Penicillin/Streptomycin (100 U/mL) at 5% oxygen, and are selected by 4 mg/mL Puromycin and 4 mg/mL G418. Suspend GNE-317 in DMSO and then diluted with the medium.GL261-GFP-Luc cells are incubated in the presence of drug or vehicle for 48 hours, and viability was assessed by MTS assay. Results were detected using a Synergy Mx automated plate reader,which are set up absorbance at 490 nm and used to determine viability and at 650 nm to account for the background. Numerical values from drug-treated wells are normalized to the values of vehicle-treated wells to yield percent survival.
Animal Research
7-week-old C57BL/6J mice are implanted GL261-GFP-Luc cells. When tumors reach 5e7 photons/s/cm2/sr (radiance), mice are orally administered the maximum tolerated the dose,which is defined as <10% drop in mice bodyweight dose, GDC-0980 for 7.5 mg/kg, GNE-317 for 30 mg/kg or vehicle once daily for 3 days. At 1 or 6 hours after the third dose, mice are euthanized with carbon dioxide and perfused with 30 mL PBS.

Storage & Handling

Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Mammalian target of Rapamycin, GNE 317, GNE-317, GNE317, inhibit, mTOR, Inhibitor, PI3K, Phosphoinositide 3-kinase

Similar Products

  • GNE-317 [orb1226374]

    >98% (HPLC)

    1394076-92-6

    414.4814

    C19H22N6O3S

    5 mg, 10 mg, 25 mg, 50 mg, 200 mg, 500 mg, 1 g, 2 mg, 100 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Protocol Information

Available Sizes

Select a size below

1 mg
$ 80.00
2 mg
$ 90.00
5 mg
$ 120.00
1 ml x 10 mM (in DMSO)
$ 130.00
10 mg
$ 170.00
25 mg
$ 260.00
50 mg
$ 410.00
100 mg
$ 500.00
200 mg
$ 710.00
DispatchUsually dispatched within 5-10 working days
Bulk Enquiry